UK markets closed
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • FTSE 250

    20,372.52
    +123.78 (+0.61%)
     
  • AIM

    968.25
    +10.25 (+1.07%)
     
  • GBP/EUR

    1.1764
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.20%)
     
  • BTC-GBP

    22,852.95
    -111.27 (-0.48%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • DOW

    33,212.96
    +575.77 (+1.76%)
     
  • CRUDE OIL

    115.07
    +0.98 (+0.86%)
     
  • GOLD FUTURES

    1,850.60
    +3.00 (+0.16%)
     
  • NIKKEI 225

    26,781.68
    +176.84 (+0.66%)
     
  • HANG SENG

    20,697.36
    +581.16 (+2.89%)
     
  • DAX

    14,462.19
    +230.90 (+1.62%)
     
  • CAC 40

    6,515.75
    +105.17 (+1.64%)
     

COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA
03.05.2022 / 06:00

Press Release (PDF)

Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.

Eleview(R) is a submucosal injectable liquid composition, developed and patented by Cosmo, intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions prior to excision with a snare or other endoscopic device.

The objective is to allow endoscopists with a faster and less risky excision of adenomas or polyps during endoscopy. The composition is injected in the submucosa, beneath the lesion to be excised, where it forms a cushion lifting the lesion and lasting up to 45 minutes. This gives the endoscopist sufficient time to cut out the lesion without the needs for repeated injections. The composition is stained with Methylene Blue, thus allowing a clear differentiation of the tissues and of the surgical area. This provides a better visibility of the surgical area and thereby reduces the risks that the colon is perforated during the procedure.

Eleview(R) is approved in the U.S., EU, Canada and Japan: The FDA approved the product in September 2015. In the EU, the product was approved in June 2016. Eleview(R) was approved by Health Canada in 2019 and in November 2020 it was approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

Eleview(R) is classified as a class II medical device in the U.S. and class IIa medical device in Europe under the Medical Device Directive 93/42/EEC and subsequent amendments.

Alessandro Della Chà, Chief Executive Officer, said: 'The signing of the agreement further strengthens our cooperation with Medtronic and allows the Eleview(R) franchise to expand on a global scale. We are looking forward to making Eleview(R) a worldwide success'.

Upcoming Calendar of Events:

Annual General Meeting 2022

27 May 2022

Half-Year Results 2022

29 July 2022

About Cosmo Pharmaceuticals
Cosmo is a pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders, to improve endoscopy quality measures through aiding the detection of colonic lesions and to treat selected dermatological conditions. Cosmo develops and manufactures products which are distributed globally including Lialda(R), Uceris(R)/Cortiment(R) and Winlevi(R). Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius(TM) which uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo(R) to Red Hill Biopharma Ltd. for the US and has licensed Relafalk(R) to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.


End of Media Release

Language:

English

Company:

Cosmo Pharmaceuticals N.V.

Riverside 2, Sir John Rogerson's

Dublin 2 Dublin

Ireland

Phone:

+ 353 1 817 0370

E-mail:

info@cosmopharma.com

Internet:

https://www.cosmopharma.com/

ISIN:

NL0011832936

Listed:

SIX Swiss Exchange

EQS News ID:

1341631


 

End of News

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting